Needham analyst Stephen Unger raised his price target on Agilent to $92 and kept his Buy rating after its "solid" Q3 results, also boosting his FY19 and FY20 EPS view by 2c to $3.08 and $3.39 respectively. The analyst is positive on the company's "diverse portfolio of solutions" addressing a variety of customer needs, with recent strategic investments targeting the shift in the pharma industry to biopharmaceuticals from small molecule drugs. Unger adds that the recent weakness in Agilent shares offer a "unique buying opportunity" for long-term investors.